About this medicine

Lorazepam can bring relatively rapid relief of anxiety but can also impair alertness. Its short-term role should be agreed with a prescriber alongside a plan for the underlying problem.

What is this medicine used for?

The Genus tablets are licensed for severe adult anxiety for 2–4 weeks, including anxiety-related insomnia, and for procedural premedication from age five. The Aristo dissolving product has different age and dose instructions.

Aristo’s paediatric exception is procedural premedication from age six, not routine anxiety treatment. Its under-six contraindication differs from Genus’s age-five procedural indication. Lorazepam is not primary treatment for depression or psychosis and should not be used alone for depression-associated anxiety.

The oral solution covers short-term severe anxiety and procedural premedication but is not recommended for children. Macure injection has separate procedural and acute-anxiety/excitement/mania indications, and is also used for status epilepticus.

Which warning signs need help?

Dependence can develop during treatment. Combining lorazepam with opioids or alcohol can cause profound sedation and breathing failure. If someone is difficult to wake or breathing abnormally, obtain emergency help immediately: 999 in the UK, or local emergency services elsewhere.

How do I take it safely?

The Genus adult anxiety schedule is 1–4 mg daily in divided doses; anxiety-related insomnia uses 1–2 mg before bed. The Aristo dissolving product gives a usual 0.5–2.5 mg daily range for anxiety-related problems. Product-specific instructions matter; these are educational label examples, not doses to select yourself.

The Aristo 1 mg tablet is scored into equal doses and dissolves on the tongue; swallowing with water is optional. The short-term plan should include an end-of-treatment review from the outset.

The checked oral liquid is 1 mg/ml and comes with an oral syringe. It requires refrigeration at 2–8°C and protection from light; after opening, its 60 ml bottle expires after 30 days and 150 ml bottle after 90 days. Follow the dispensed pack’s instructions.

Macure 4 mg/ml injection is administered intravenously or intramuscularly; intravenous use is preferred in its label. Intramuscular absorption is slower and need not act faster than oral lorazepam. It is not for chronic treatment.

What side effects should I know about?

Sleepiness, dizziness, unsteadiness and muscle weakness are recognised effects. New agitation, unusual behaviour, confusion or memory difficulties should be discussed promptly with the prescriber.

Who needs extra care with this medicine?

Severe breathing or liver problems, sleep apnoea and myasthenia gravis can rule out treatment. Older people are more vulnerable to falls and often need lower doses.

The Aristo product additionally contraindicates acute intoxication with alcohol or other central depressants and a history of alcohol or drug dependence. These product-specific restrictions require prescriber assessment, not judgement or abrupt withdrawal of established treatment.

Can it affect my other medicines?

Tell the prescriber about other sedating medicines, including opioid pain medicines and sedating antihistamines. Valproate can increase lorazepam exposure; clozapine combinations need particular caution. Avoid alcohol.

What check-ups will I need?

Review benefit, sleepiness, falls, mood and the continuing need for treatment. Tell the clinician if the same dose seems less effective or taking more becomes difficult to resist. These concerns need support.

If repeated courses are clinically necessary, the SmPC recommends periodic blood counts and liver-function assessment. Kidney or liver impairment requires closer supervision and potentially lower dosing. For bedtime use, allow adequate uninterrupted sleep because memory and next-day functioning can be impaired.

Macure requires facilities to support breathing and observation for at least eight hours, preferably overnight; an outpatient must leave accompanied. Its benzyl alcohol and propylene glycol add particular neonatal/young-child and organ-impairment cautions. Preparation and seizure-treatment protocols belong to trained clinical teams.

What about pregnancy, breastfeeding and age?

Pregnancy and breastfeeding need a specific risk–benefit discussion. Exposure near birth can affect the baby’s breathing, feeding or adaptation. Childhood procedural use does not authorise routine treatment of childhood anxiety.

Macure is not recommended below twelve for premedication or acute anxiety, but its status-epilepticus section includes paediatric use. These are not the oral products’ age limits.

What if I miss a dose or want to stop?

Do not abruptly stop regular lorazepam: withdrawal may include seizures. The dose is reduced according to an agreed plan. Do not double a missed dose; the leaflet gives different timing advice for anxiety and bedtime use.

How does it work?

Lorazepam helps nerve cells respond more strongly to GABA, a chemical messenger that usually quiets their activity. This can ease anxiety, but the same effect can make a person sleepy or less coordinated. It belongs to the benzodiazepine family of medicines.

How Brain Cells Communicate

Brain cells communicate by releasing chemical messengers across small gaps called synapses. A messenger reaches the next cell by attaching to a receptor, a protein that receives its signal. GABA acts at several kinds of receptor; the GABA-A receptor is a channel through which electrically charged particles can move. In many adult brain cells, opening this channel makes it harder for the cell to send another electrical signal.

What is known: GABA-A receptors help restrain activity in connected groups of nerve cells.

What remains uncertain: These connections also participate in memory, movement and alertness.

GABA-A signaling

A GABA-A channel with ochre GABA symbols at outer sites and lavender chloride ions in an open pore. Chloride · Cl−: Inward movement is a typical mature-cell example; ion gradients can differ. GABA-A receptor / channel: GABA activates this ion channel. Open channel: The arrow shows a qualitative direction, not an ion count or measured rate.

Optional motion shows inward ion movement in this example. Counts and timing are illustrative.

  1. Chloride · Cl−

    Inward movement is a typical mature-cell example; ion gradients can differ.

  2. GABA-A receptor / channel

    GABA activates this ion channel.

  3. Open channel

    The arrow shows a qualitative direction, not an ion count or measured rate.

Simplified teaching model. Protein shapes, sizes, particle counts and arrows are illustrative, not measurements or experimental structures.

GABA acts at GABA-A receptor channels. Inward chloride movement is a typical mature-cell example; the effect depends on the cell and ion gradients.

GABA-A receptors help restrain activity in connected groups of nerve cells. Simplified illustration of the process; individual responses vary.
About this illustration

GABA: inhibitory messenger. These connections also participate in memory, movement and alertness.

Conceptual pathway · not to scale · arrows show relationships, not measured rates

How the Medication Changes Signaling

Lorazepam attaches to a particular part of the GABA-A receptor called the benzodiazepine site. This site is separate from the place where GABA attaches, so lorazepam strengthens the response to GABA already present. The resulting increase in inhibition, meaning reduced nerve-cell activity, helps explain both calming and sedating effects.

What is known: Its action depends on enhancing an existing GABA signal.

What remains uncertain: Receptor activity cannot tell us how much anxiety relief one person will feel.

Lorazepam and GABA-A

A GABA-A channel with GABA at outer sites and a separate modulator at a side site; the pore remains open for chloride. Chloride · Cl−: Inward movement is a typical mature-cell example; ion gradients can differ. GABA-A receptor / channel: GABA activates this ion channel. Lorazepam: GABA response enhanced: The medicine symbol labels an action, not an experimentally determined binding position.
  1. Chloride · Cl−

    Inward movement is a typical mature-cell example; ion gradients can differ.

  2. GABA-A receptor / channel

    GABA activates this ion channel.

  3. Lorazepam: GABA response enhanced

    The medicine symbol labels an action, not an experimentally determined binding position.

Simplified teaching model. Protein shapes, sizes, particle counts and arrows are illustrative, not measurements or experimental structures.

Lorazepam enhances GABA-mediated signaling through GABA-A receptor complexes. The medicine does not replace GABA or block the pore.

Its action depends on enhancing an existing GABA signal. Simplified illustration of the process; individual responses vary.
About this illustration

Lorazepam: benzodiazepine site. Receptor activity cannot tell us how much anxiety relief one person will feel.

Conceptual pathway · not to scale · arrows show relationships, not measured rates

A Closer Look at the Molecular Level

With repeated exposure, the nervous system can adapt to lorazepam being present. This can produce physical dependence: the body has adjusted enough that a sudden reduction can cause withdrawal symptoms, including severe reactions such as seizures. This adaptation can happen during prescribed treatment and does not, by itself, mean someone has an addiction.

What is known: Opioid medicines, such as morphine for pain, and other medicines that cause sleepiness can add to lorazepam’s effects on breathing and alertness.

What remains uncertain: The degree of adaptation and the course of withdrawal vary between people.

Lorazepam · what the mechanism can explain

  1. Receptor actionGABA signaling
  2. Repeated exposureadaptation may occur
  3. Sudden withdrawalcan be dangerous
Opioid medicines, such as morphine for pain, and other medicines that cause sleepiness can add to lorazepam’s effects on breathing and alertness. Simplified illustration of the process; individual responses vary.
About this illustration

Receptor action: GABA signaling. The degree of adaptation and the course of withdrawal vary between people.

Conceptual pathway · not to scale · arrows show relationships, not measured rates

How does it affect my body?

Calming and sleepiness may appear within roughly half an hour after oral treatment. Concentration and coordination can remain impaired, so feeling calmer does not establish fitness to drive.

How does my body process it?

Lorazepam is converted mainly to an inactive glucuronide rather than major active metabolites. The Genus label reports an elimination half-life of about 12 hours.

How do treatment options differ?

NICE restricts benzodiazepines for generalised anxiety to brief crisis use. Longer-term care may involve psychological therapy or other medicines. Benzodiazepine doses are not interchangeable milligram for milligram.

A closer look at the science

It belongs to the 1,4-benzodiazepines. Binding at benzodiazepine sites functionally linked to GABA receptors enhances GABA-mediated inhibition; it does not replace GABA.

The image shows the verified lorazepam molecular identity used in the article. It does not depict inactive ingredients or a receptor-bound conformation.

Chemical formula: C15H10Cl2N2O2

C, H, N, O and Cl stand for carbon, hydrogen, nitrogen, oxygen and chlorine where present. Subscripts count atoms. The formula identifies composition, not clinical potency or a dose.

Verified 2D PubChem depiction of lorazepam.
NCBI PubChem CID 3958. Skeletal lines represent bonds; unlabeled corners and line ends are carbon, and many hydrogens are omitted. This is connectivity, not a receptor binding pose.

A 2D structure does not show the full range of conformations or predict treatment response.

How was this medicine developed?

Ativan is a recognised search name for lorazepam. The products verified here are generic Genus tablets and an Aristo dissolving tablet; an alias does not establish a particular brand’s current supply.

Ativan oral tablets received US approval in September 1977. This is an international development milestone, not the authorisation date or current supply status of a UK product.

Sources and References

  1. NHS: common questions about lorazepam

    Scope: NHS website medicines information (England); not a guarantee of identical services across UK nations.

  2. Lorazepam 1 mg tablets — SmPC, sections 4.1–4.9, 5.1–5.2 and 7–10

    Product information published on the electronic Medicines Compendium (emc); supplied by pharmaceutical companies.

    Scope: United Kingdom product information.

  3. Lorazepam Aristo 1 mg orodispersible tablets — SmPC, sections 4.1–4.9, 5.1–5.2 and 7–10

    Product information published on the electronic Medicines Compendium (emc); supplied by pharmaceutical companies.

    Scope: United Kingdom product information.

  4. Lorazepam 1 mg and 2.5 mg tablets — patient leaflet, sections 1–4 and 6

    Product information published on the electronic Medicines Compendium (emc); supplied by pharmaceutical companies.

    Scope: United Kingdom product information.

  5. Strengthened information on dependence, addiction, withdrawal and tolerance — benzodiazepines, Z-drugs and gabapentinoids

    Scope: United Kingdom.

  6. NICE CG113: generalised anxiety and panic disorder — drug-treatment recommendations on benzodiazepines

    Scope: NICE guidance for England; application in other UK nations determined separately.

  7. Oral benzodiazepines and choosing equivalent doses — differences and licensed indications

    Scope: NHS Specialist Pharmacy Service (England), professional medicines advice.

  8. Lorazepam: original product approval and regulatory history

    Scope: United States; historical approval only.

  9. Lorazepam Macure 4 mg/ml solution for injection — SmPC

    Product information published on the electronic Medicines Compendium (emc); supplied by pharmaceutical companies.

    Scope: United Kingdom; named product information.

  10. Lorazepam 1 mg/ml oral solution — SmPC

    Product information published on the electronic Medicines Compendium (emc); supplied by pharmaceutical companies.

    Scope: United Kingdom; named product information.

  11. Loreev XR prescribing information — receptor mechanism and formulation distinction

    Scope: Shared scientific explanation; source remains US, not UK prescribing authority.

  12. Lorazepam: current product prescribing information

    Scope: Shared scientific explanation; source remains US, not UK prescribing authority.

  13. Lorazepam: verified parent compound, PubChem CID 3958

    Scope: International chemical reference.

  14. NIMH: Understanding psychosis

Shared scientific background. US product pharmacology and chemical references do not establish UK licences, doses, formulations or NHS recommendations.

Was this article helpful?

Was this article helpful?

Sends your choice, article identifier, edition and optional issue to Psychiatry Atlas. No name, email or medical details are requested. Daily network codes help prevent spam; hosting may process technical information. This is not a promise of anonymity. Privacy details.

Enable JavaScript to send feedback.

Suggest a missing topic or describe a correction. Please keep personal medical information out of website feedback.

Back to top